Biocon Biologics' Insugen awarded a 3-year contract by Health Ministry, Malaysia

27 Apr 2022 , 09:16 AM

Biocon Biologics Limited, a subsidiary of Biocon Ltd has announced that its subsidiary Biocon Sdn. Bhd. in Malaysia has been awarded a 3-year contract, valued at USD 90 million (MYR 375 million), for its recombinant human insulin brand Insugen, by the Ministry of Health (MoH), Malaysia.

Biocon Sdn. Bhd. a subsidiary of Biocon Biologics in Malaysia, will manufacture and supply its range of insulins to its partner Duopharma Marketing Sdn. Bhd. (DMktg), a subsidiary of Duopharma Biotech, a  leading pharmaceutical and biotech company in Malaysia.

Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health Hospitals, districts health offices and health clinics.

On Wednesday early morning trade, Biocon was trading at Rs377.45 per piece lower by 0.63% on the BSE.